PBGENE-HBV is designed to potentially cure chronic hepatitis B by eliminating the root cause of the virus. The Food and Drug Administration (FDA) has granted Fast Track designation to PBGENE-HBV, an ...

Chronic HBV was associated with increased risk for adverse COVID-19 outcomes, but the risk was lower among coinfected patients vaccinated against COVID-19.

Immunocore Holdings' stock has dropped 60% as Kimmtrak faces market saturation, but its pipeline could offer potential. Find ...

The session titled “Defeating Cancer by Curing Infections” at European Society of Clinical Microbiology and Infectious ...

Functional cure, defined as durable hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) DNA titers below the ...

Hepatitis D virus (HDV) infects the liver and causes severe inflammation. According to WHO estimates, 12 million people ...

Ascentage Pharma Group International’s AAPG share price has surged by 7.56%, which has investors questioning if this is right ...

Explore seven biotech companies advancing clinical drugs in the race for regulatory approval to revolutionize hepatitis B ...

Cirrhosis progresses in stages, from a compensated phase with few symptoms to a decompensated phase with serious ...

Fatigue and yellowing eyes may signal hepatitis, a serious liver issue. Learn the symptoms, causes, prevention, and available ...

Hepatitis viruses A to E differ in transmission and severity, ranging from foodborne infections to bloodborne risks. We got ...